Compare Quest Diagnostics Inc (DGX) vs iShares MSCI France ETF (EWQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares MSCI France ETF — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while iShares MSCI France ETF trades at $41.52 (market cap $330.91M). The key difference: Quest Diagnostics Inc is far larger — about 77× iShares MSCI France ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares MSCI France ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares MSCI France ETF for 55 Days on average.
| DGX | EWQ | |
|---|---|---|
Market Cap | $25.48B | $330.91M |
Volume | 941,866 | 556,654 |
Sector | Health | Broad Market / Factor |
52-Week High | $247.45 | $48.35 |
52-Week Low | $173.49 | $41.32 |
Typical Hold Time | 56 Days | 55 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
EWQ is trading at $41.52 with a slight 0.44% daily gain, though technical indicators show a bearish bias with moving averages signaling strong selling pressure. The stock faces mixed sentiment with oscillators suggesting potential oversold conditions while European market uncertainties create headwinds. Recent news highlights ECB rate hikes and energy-driven inflation concerns affecting European equities.
The stock's outlook remains cautious with technical weakness offset by potential oversold bounce opportunities. Key risks include European economic sentiment deterioration and persistent inflation pressures, while the absence of fundamental data requires careful monitoring of upcoming financial disclosures for valuation clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →
